DEVELOPING INNOVATIVE CELLULAR THERAPIES FOR CNS DISEASE
A UNIQUE APPROACH
Q Therapeutics has adopted a unique approach to developing human cell-based therapies for debilitating – and currently incurable – diseases of the brain and spinal cord (the central nervous system, or CNS). Our revolutionary approach focuses on glial cells – non-neuronal cells in the CNS that are essential for supporting, repairing and maintaining normal neuron function and health.
Q-Cells® – our first cellular therapeutic candidate – are human glial progenitor cells that give rise to two types of specialized glial cells, astrocytes and oligodendrocytes. In pre-clinical studies, Q-Cells® have been shown to successfully replicate, migrate and differentiate at sites of CNS injury and disease, with resulting improvements in both function and survival, and no observed toxicity.
Q Thera now has FDA allowance for an IND application to proceed with a Phase 1/2a clinical trial of Q-Cells® in patients with Transverse Myelitis, a crippling inflammation of the spinal cord that affects approximately 40,000 people in the US. Similar to Multiple Sclerosis, TM destroys the myelin sheath surrounding nerve fibers in the spinal cord, compromising muscle control and affecting sensation.